Search

Rocket Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

3.47 4.2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.27

Massimo

3.49

Metriche Chiave

By Trading Economics

Entrata

171M

123M

EPS

-0.15

Dipendenti

202

EBITDA

-1.9M

-47M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+234.43% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.3M

397M

Apertura precedente

-0.73

Chiusura precedente

3.47

Notizie sul Sentiment di mercato

By Acuity

27%

73%

97 / 340 Classifica in Healthcare

Rocket Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 22:01 UTC

Rocket Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified. Broader market concerns may be influencing the decline.

13 ago 2026, 19:56 UTC

Rocket Pharmaceuticals Inc shares are lower today, continuing a recent downward trend amid rising U.S. unemployment claims, with no specific company news identified.

12 ago 2026, 19:16 UTC

Rocket Pharmaceuticals Inc shares are lower today, with no specific news driving the decline. Earlier, the stock reached a session high before falling.

11 ago 2026, 20:02 UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

10 ago 2026, 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

8 ago 2026, 00:01 UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

7 ago 2026, 23:01 UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

6 ago 2026, 23:06 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

5 ago 2026, 20:02 UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

4 ago 2026, 19:26 UTC

News
Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

3 ago 2026, 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31 lug 2026, 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30 lug 2026, 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29 lug 2026, 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28 lug 2026, 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27 lug 2026, 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24 lug 2026, 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22 lug 2026, 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20 lug 2026, 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Confronto tra pari

Modifica del prezzo

Rocket Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

234.43% in crescita

Previsioni per 12 mesi

Media 11.17 USD  234.43%

Alto 15 USD

Basso 5 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rocket Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

5

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

97 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat